Pharma

Pharmalot

Pharmalittle: Researchers identify 70 drugs for possibly fighting Covid-19; Gilead pauses access to experimental drug

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Trump adviser slams PhRMA pushback against ‘American-made’; drug makers boost production of malaria pill for Covid-19

By Ed Silverman

Pharmalot

Teva and Mylan to jumpstart production of old malaria drug to fight the novel coronavirus

By Ed Silverman

Pharmalot

Preventing other Shkreli-like debacles may not save the government much money

By Ed Silverman

Pharmalot

Pharmalittle: WHO to launch expansive coronavirus clinical trial; FDA halts some domestic inspections

By Ed Silverman

Pharmalot

Coronavirus will have a ‘big impact’ on one-third of U.S. clinical trial sites, survey finds

By Ed Silverman

Pharma

Pharmalittle: Blood samples are lacking for coronavirus treatments; Europe counters Trump offer to vaccine maker

By Ed Silverman

Pharmalot

Pharmalittle: FDA gives states an OK to authorize coronavirus tests; more companies race to combat Covid-19

By Ed Silverman

Biotech

Merck drug reduces cough frequency but taste alterations could cloud prospects

By Adam Feuerstein

Pharmalot

Global spending on drugs may hit $1.1 trillion by 2024, but the rate of growth is forecast to slow

By Ed Silverman

Pharmalot

FDA moves to boost coronavirus testing capacity by giving states more power

By Ed Silverman

Pharmalot

Mallinckrodt loses a court case and is on the hook for $650 million in overdue Medicaid rebates

By Ed Silverman

Pharmalot

Novartis is scolded by Finnish regulators over hospital sales of a migraine drug

By Ed Silverman

Pharmalot

Pharmalittle: Will countries nationalize anti-coronavirus supplies? Pandemic halts some academic labs

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Drug makers scramble to develop Covid-19 vaccines; Qiagen vows to ramp up production of test chemical

By Ed Silverman

Pharmalot

Pharmalittle: A move to fund U.S. production of pharma ingredients; White House issues ‘principles’ for drug pricing reform

By Ed Silverman

Pharmalot

Danish regulator eyes sanctions — including prison time — against trial sponsors that fail to post results

By Ed Silverman

Pharmalot

Under pressure, Trump administration looks to cap insulin costs with a Medicare program

By Ed Silverman

Pharmalot

Coronavirus fears may slow clinical trials and delay regulatory steps

By Ed Silverman

Pharmalot

Pharmalittle: Shortage of a key chemical slows coronavirus testing; CMS touts pilot program to lower insulin costs

By Ed Silverman

Pharmalot

Pharmalittle: Gates Foundation and others plan $125 million coronavirus effort; India considers lifting export restrictions

By Ed Silverman

Pharmalot

Clinical research company sued over stolen trade secrets after employee filmed dogs used in experiments

By Ed Silverman

Pharmalot

Debates over biosimilar uptake notwithstanding, sales growth should accelerate by 2024

By Ed Silverman

Pharmalittle: Pharmacy boards limit prescriptions for drugs touted by Trump; nearly half of trial sites expect disruptions

Ecuador becomes the latest country to eye compulsory licensing for Covid-19 products

An Indian drug maker is slammed by FDA for tossing ‘cartloads of trash bags’ filled with documents

AbbVie waives all worldwide restrictions on making generic copies of its Kaletra HIV pill

Pharmalittle: Researchers identify 70 drugs for possibly fighting Covid-19; Gilead pauses access to experimental drug

Up and down the ladder: The latest comings and goings

Pharmalittle: Trump adviser slams PhRMA pushback against ‘American-made’; drug makers boost production of malaria pill for Covid-19

Teva and Mylan to jumpstart production of old malaria drug to fight the novel coronavirus

Preventing other Shkreli-like debacles may not save the government much money

Pharmalittle: WHO to launch expansive coronavirus clinical trial; FDA halts some domestic inspections

Coronavirus will have a ‘big impact’ on one-third of U.S. clinical trial sites, survey finds

Pharmalittle: Blood samples are lacking for coronavirus treatments; Europe counters Trump offer to vaccine maker

Pharmalittle: FDA gives states an OK to authorize coronavirus tests; more companies race to combat Covid-19

Merck drug reduces cough frequency but taste alterations could cloud prospects

Global spending on drugs may hit $1.1 trillion by 2024, but the rate of growth is forecast to slow

FDA moves to boost coronavirus testing capacity by giving states more power

Mallinckrodt loses a court case and is on the hook for $650 million in overdue Medicaid rebates

Novartis is scolded by Finnish regulators over hospital sales of a migraine drug

Pharmalittle: Will countries nationalize anti-coronavirus supplies? Pandemic halts some academic labs

Up and down the ladder: The latest comings and goings

Pharmalittle: Drug makers scramble to develop Covid-19 vaccines; Qiagen vows to ramp up production of test chemical

Pharmalittle: A move to fund U.S. production of pharma ingredients; White House issues ‘principles’ for drug pricing reform

Danish regulator eyes sanctions — including prison time — against trial sponsors that fail to post results

Under pressure, Trump administration looks to cap insulin costs with a Medicare program

Coronavirus fears may slow clinical trials and delay regulatory steps

Pharmalittle: Shortage of a key chemical slows coronavirus testing; CMS touts pilot program to lower insulin costs

Pharmalittle: Gates Foundation and others plan $125 million coronavirus effort; India considers lifting export restrictions

Clinical research company sued over stolen trade secrets after employee filmed dogs used in experiments

Debates over biosimilar uptake notwithstanding, sales growth should accelerate by 2024